Galapagos NV (NASDAQ:GLPG) Receives Average Rating of “Hold” from Brokerages

Shares of Galapagos NV (NASDAQ:GLPG) have received a consensus rating of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $36.50.

Several equities research analysts have recently weighed in on GLPG shares. Royal Bank Of Canada increased their price target on Galapagos from $32.00 to $33.00 and gave the stock a “sector perform” rating in a report on Tuesday, February 24th. Wall Street Zen raised Galapagos from a “sell” rating to a “hold” rating in a research report on Tuesday, December 30th. Raymond James Financial reiterated a “market perform” rating on shares of Galapagos in a research note on Tuesday, February 24th. UBS Group reiterated a “market perform” rating on shares of Galapagos in a research report on Tuesday, February 24th. Finally, Weiss Ratings raised shares of Galapagos from a “sell (d)” rating to a “hold (c)” rating in a research note on Thursday, February 26th.

Galapagos Price Performance

Shares of NASDAQ GLPG opened at $31.71 on Friday. Galapagos has a 1 year low of $22.59 and a 1 year high of $37.78. The firm has a 50-day simple moving average of $33.63 and a two-hundred day simple moving average of $32.83.

Institutional Investors Weigh In On Galapagos

Large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC increased its position in shares of Galapagos by 2,245.7% during the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock worth $2,783,000 after acquiring an additional 115,946 shares during the period. Geode Capital Management LLC purchased a new stake in shares of Galapagos in the second quarter valued at approximately $220,000. XTX Topco Ltd purchased a new stake in shares of Galapagos in the second quarter valued at approximately $1,114,000. Norges Bank bought a new position in Galapagos in the second quarter worth approximately $3,359,000. Finally, Jump Financial LLC bought a new position in Galapagos in the second quarter worth approximately $692,000. 32.46% of the stock is owned by hedge funds and other institutional investors.

About Galapagos

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.